Rosiglitazone: a new therapy for Type 2 diabetes

Bibliography

• PERRY C, PETRIE JR: Insulin-sensitising agents. Emerging Drugs (1998) 3:247–260.
   Google Scholar
• HENRY RR: Prospects for primary prevention of Type II or non-insulin-dependent diabetes mellitus. Diabetes Rev Int. (1994) 3:2–5.
   Google Scholar
• HENRY RR: Glucose control and insulin resistance innon-insulin-dependent diabetes mellitus. Ann. Intern. Med. (1996) 124:97–103.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in thetreatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• •Good basic science and early clinical review of thiazolidinediones.
   Google Scholar
• OLEFSKY JM: Pathogenesis of non-insulin-dependent (type II) diabetes. In: Endocrinology (Second Edition). DeGroot LJ, Besser GM, Cahill GF Jr et al. (Eds.), WB Saunders Co, Philadelphia, PA (1989)2:1369–1388.
   Google Scholar
• OPARA JU, LEVINE JH: The deadly quartet-the insulin resistance syndrome. South Med. J. (1997) 90:1162–1168.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• ••Landmark 15-year study on the effect of glycaemic controlon complications associated with Type 2 diabetes.
   Google Scholar
• BUCKINGHAM RE, AL-BARAZANJI KA, TOSELAND CDN et Peroxisome proliferator-activated receptor-y agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes (1998) 47:1326–1334.
   PubMed Web of Science ®Google Scholar
• ••Seminal study in the Zucker fatty rat model of impairedglucose tolerance demonstrating that rosiglitazone decreased renal injury and pancreatic islet damage. WHITCOMB RW, SALTIEL AR: Thiazolidinediones. Exp. Opin. Invest. Drugs (1995) 4:1299-1309. PARKE-DAVIS PHARMACEUTICALS: (1998) Rezulin package insert. CANTELLO BCC, CAWTHORNE MA, HAIGH D et al: The synthesis of BRL 49653-a novel and potent antihyper-glycemic agent. Bioorg. Med. Chem. Lett. (1994) 4:1181–1184.
   Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPARy). J. Biol. Chem. (1995) 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• ••Pivotal mechanism of action paper suggesting that theadipogenic and antidiabetic effects of thiazolidinedione are due to activation of the PPARy.
   Google Scholar
• ELDERSHAW TPD, RATTIGAN S, CAWTHORNE MA, BUCKINGHAM RE, COLQUHOUN EQ, CLARK MG: Treatment with thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. Horm. Metab. Res. (1995) 27:169–175.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrates effectiveness of rosiglitazone inreducing peripheral insulin resistance in the obese rat model.
   Google Scholar
• SMITH SA, CAWTHORNE MA, COYLE PJ eta].: BRL 49653 normalises glycaemic control in Zucker fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin [abstract 707]. Diabetologia (1993) 36\(Suppl. 1):A184.
   Google Scholar
• OAKES ND, KENNEDY CJ, JENKINS AB et al: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes (1994) 43:1203–1210.
   PubMed Web of Science ®Google Scholar
• •Seminal study suggests that improvements in insulin action and glucose metabolism with rosiglitazone is mediated in part by reductions in lipid availability.
   Google Scholar
• YOUNG PW, CAWTHORNE MA, COYLE PJ et al.: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes (1995) 44:1087–1092.
   PubMed Web of Science ®Google Scholar
• •Study suggests that improvements in insulin action with rosiglitazone is due in part to increased glucose transport in adipocytes.
   Google Scholar
• DEVOS P, LEFEBVRE A-M, MILLER SG et al.: Thiazolidine-diones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor y. j Clin. Invest. (1996) 98:1004–1009.
   PubMed Web of Science ®Google Scholar
• SOUZA SC, YAMAMOTO MT, FRANCIOSA MD et al: BRL49653 blocks the lipolytic actions of tumor necrosis factor-a. Diabetes (1998) 47:691–695.
   PubMed Web of Science ®Google Scholar
• TAI T-A C, JENNERMANN C, BROWN KK et al:Activation of the nuclear receptor peroxisome proliferator-activated receptor y promotes brown adipocyte differ-entiation. J. Biol. Chem. (1996) 271:29909–29914.
   PubMed Web of Science ®Google Scholar
• TERUEL T, SMITH S: Differential regulation of UCP-1 expression by rosiglitazone and Wy 14643 in brown adipocytes [abstract 0066]. Diabetes (1998) 47 (Suppl. 1):A17.
   Google Scholar
• FINEGOOD DT, MCARTHUR MD, DUNICHAND-HOEDL A et al. The PPARy agonist, rosiglitazone, reverses hyperinsulinemia and promotes growth of islet 8-cell mass [abstract 0182]. Diabetes (1998) A7\(Suppl 1) A47
   Google Scholar
• CONNOR SC, HUGHES MG, MOORE G, LISTER CA, SMITHSA: Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 111 NMR studies of urine. J. Pharm. Pharmacol. (1997) 49:336–344.
   PubMed Web of Science ®Google Scholar
• SMITH S, BOAM D, BRETHERTON-WATT D et al.: Rosigli-tazone increases pancreatic islet area, density and insulin content, but not insulin gene expression [abstract 0072]. Diabetes (1998) 47 (Suppl. 1):A18.
   Google Scholar
• PATEL J, ANDERSON RJ, RAPPAPORT EB: Rosiglitazone monotherapy improves glycemic control in patients with Type 2 diabetes: a 12-week randomized, placebo-controlled study. Diabetes Obes. Metab. (1999) (In Press).
   Google Scholar
• ••Dose-ranging clinical trial demonstrating the effectivenessof rosiglitazone in patients with Type 2 diabetes.
   Google Scholar
• KUMAR S, BOULTON AJM, BECK-NIELSEN H et al.: Trogli-tazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• FREED MI, ALLEN A, JORKASKY DK et al.: The bioavail-ability of rosiglitazone is unaltered by food. Eur. J. Clin. Pharmacol (1999) 55:53–56.
   PubMed Web of Science ®Google Scholar
• •Important clinical study demonstrating that rosiglitazone is effective if taken with or without food.
   Google Scholar
• WOLFFENBUTTEL BHR, GRAAL MB: New treatments for patients with Type 2 diabetes mellitus. Postgrad. Med. J. (1996) 72:657–662.
   PubMed Web of Science ®Google Scholar
• BAILEY CJ, TURNER RC: Drug therapy: metformin. New Engl. J. Med. (1996) 334;574–579.
   PubMed Web of Science ®Google Scholar
• PATEL J, MILLER E, PATWARDHAN R, THE ROSIGLITA-ZONE 011 STUDY GROUP: Rosiglitazone (BRL 49653) monotherapy has significant glucose lowering effect in Type 2 diabetic patients [abstract 0067]. Diabetes (1998) 47 (Suppl. 1):A17.
   Google Scholar
• GOMIS R, JONES NP, VALLANCE SE, PATWARDHAN R: Low dose rosiglitazone provides additional glycemic control when combined with sulfonylureas in Type 2 diabetes. [abstract 0266]. Diabetes (1999) 48\(Suppl. 1):A63.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• •Substudy of landmark UKPDS demonstrating that intensive glucose control with metformin in overweight diabetic patients reduced diabetes-related complications.
   Google Scholar
• FONSECA V, BISWAS N, SALZMAN A: Once daily rosigli-tazone in combination with metformin effectively reduces hyperglycemia in patients with Type 2 diabetes. Diabetes (1999) 48 (Suppl. 1):A100.
   Google Scholar
• SCHWARTZ S, RASKIN P, FONSECA V et al.: Effect of troglitazone in insulin-treated patients with Type II diabetes mellitus. New Engl. J. Med. (1998) 338:861–866.
   PubMed Web of Science ®Google Scholar
• RASKIN P, DOLE JF, RAPPAPORT EB: Rosiglitazone improves glycemic control in poorly controlled, insulin-treated Type 2 diabetes. [abstract 0404]. Diabetes (1999) 48 (Suppl. 1):A94.
   Google Scholar
• DICICCO RA, ALLEN A, JORKASKY DK, FREED MI: Chronic administration of rosiglitazone (RSG) does not alter the pharmacokinetics of digoxin [abstract 1364]. Diabetes (1998) 47 (Suppl. 1):A353.
   Google Scholar
• FREED MI, MILLER AK, JORKASKY DK et al.: Rosiglitazone pharmacokinetics are not affected by coadministra-tion of ranitidine [abstract 1365]. Diabetes (1998) 47 (Suppl. 1):A353.
   Google Scholar
• INGLIS AML, MILLER AK, THOMPSON KA et al: Coadmin-istration of rosiglitazone and acarbose (A): lack of a clinically relevant pharmacokinetic drug interaction [abstract 1366]. Diabetes (1998) 47 (Suppl. 1):A353.
   Google Scholar
• HARRIS RZ, INGLIS AML, MILLER AK et al.: Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J. Clin. Pharmacol. (1999) (In Press).
   Google Scholar